Перейти к главному меню навигации Перейти к основному контенту Перейти к нижнему колонтитулу сайта

№ 1 (2022)

ПСИХОФАРМАКОТЕРАПИЯ

Стратегии коррекции антипсихотик индуцированной гиперпролактинемии

https://doi.org/10.21265/PSYPH.2022.60.1.003

Опубликован 2022-03-30

  • В.В. Становая
    • ,
  • М.В. Иванов

В.В. Становая
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации

М.В. Иванов
ФГБУ «Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева» Министерства здравоохранения Российской Федерации

Аннотация

Назначение антипсихотических препаратов наряду с исследованием их терапевтической эффективности требует не менее внимательного контроля и изучения показателей безопасности их применения. Из числа нейроэндокринных расстройств проявления гиперпролактинемии относятся к числу наиболее часто возникающих побочных эффектов при проведении психотропной медикаментозной терапии. Конвенциональные антипсихотики представляют наибольший риск в отношении повышения концентрации пролактина в сыворотке крови, однако применение антипсихотиков второй и последующих генераций также нередко может сопровождаться аналогичными проявлениями.  Как известно повышенный уровень пролактина подавляет высвобождение лютеинизирующего и фолликулостимулирующего гормона из гипофиза, что в последующем может привести к таким краткосрочным и долгосрочным последствиям, как нарушения менструального цикла, галакторея, сексуальная дисфункция, гинекомастия, бесплодие, снижение минеральной плотности костной ткани и рак молочной железы. Для предотвращения вышеуказанных нарушений, обусловленных повышенной секреций пролактина, крайне важно подобрать оптимальную схему приема антипсихотических препаратов с возможностью включения в неё также средств, обладающих влиянием на проявления гиперпролактинемии. Таким образом в данном литературном обзоре будут рассмотрены ряд стратегий коррекции антипсихотик индуцированной гиперпролактинемии, перспективность которых подтверждается установленной эффективностью их применения.

Ключевые слова

антипсихотик индуцированная гиперпролактинемия, лечение гиперпролактинемии

PDF

Библиографические ссылки

  1. Veldhuis JD, Johnson ML. Operating characteristics of the hypothalamo-pituitary-gonadal axis in men: circadian, ultradi- temperature and heart rate in endogenous de-pressives and an, and pulsatile release of prolactin and its temporal coupling with lute-inizing hormone // J Clin Endocrinol Metab. – 1988. – Vol. 67. – P. 175-184.
  2. Petty RG. Prolactin and antipsychotic medications: mechanism of action // Schizophr Res. – 1999. – Vol.1(35). – P.67-73.
  3. Vuk Pisk S, Matić K, Gereš N, Ivezić E, Ruljančić N, Filipčić I. Hyperprolactinemia - side effect or part of the illness // Psychiatr Danub. – 2019. – Vol. 31(2). – P.148-152.
  4. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management // Drugs. – 2004. – Vol. 64. – P. 2291-2314.
  5. Bernard V, Young J, Binart N. Prolactin – A pleiotropic factor in health and disease // Nat Rev Endocrinol. – 2019. – Vol.15. – P.356-365.
  6. Горобец Л.Н., Мазо Г.Э. Гиперпролактинемия при использовании антипсихо-тиков второго поколения: принципы профилактики, диагностики и коррекции // Обозрение психиатрии и медицинской психологии имени В.М.Бехтерева. – 2017. – №1. – C. 63-69.
  7. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review // CNS Drugs. – 2014. – Vol.28(5). – P.421- 453.
  8. Byerly M, Suppes T, Tran QV, et al.Clinical implications of anti-psychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disor-ders: recent developments and cur-rent perspectives //J Clin Psychopharmacol. – 2007. – Vol.27. – P. 639–661.
  9. Svestka J, Synek O, Tomanová J, et al. Differences in the effect of sec-ond-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients // Neuro Endocrinol Lett. – 2007. – Vol.28. – P.881–888.
  10. Wang CY, Xiang YT, Cai ZJ, Weng YZ, Bo QJ, Zhao JP, Liu TQ, Wang GH, Weng SM, Zhang HY, Chen DF, Tang WK, Ungvari GS; Risperidone Maintenance Treat-ment in Schizophrenia (RMTS) investigators. Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial // Am J Psychiatry. – 2010. – Vol.167(6). – P.676-685.
  11. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH. A comparison of weight change during treatment with olanzapine or ari-piprazole: results from a randomized, double-blind study // J Clin Psychiatry. – 2004. – Vol.65. – P.47-56.
  12. Taylor D. Antipsychotic polypharmacy-confusion reigns // The Psychiatrist. – 2010. – Vol.34. – P.41–43.
  13. Yuan H-N, Wang C-Y, Sze CW, Tong Y, Tan Q-R, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-induced hy-perprolactinemia in patients with schizophrenia // Journal of clinical psychopharmacol-ogy. – 2008. – Vol. 28. – P.264–370.
  14. Kim KS, Pae CU, Chae JH, Bahk WM, Jun TY, Kim DJ, Dickson RA. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risper-idone // J Clin Psychiatry. – 2002. – Vol.63(5). – P.408-413.
  15. Kinon BJ, Ahl J, Liu-Seifert H, Maguire GA. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine // Psychoneuroendocrinology. – 2006. – Vol. 31. – P.577- 588.
  16. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in pa-tients with schizophrenia // Biol Psychiatry. – 2009. – Vol.65(6). – P.:510-517.
  17. Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, Bergstrom RF. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration // J Clin Psychopharmacol. – 2009. – Vol.29(3). – P.278-83.
  18. Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Lieberman JA. Prolactin levels in schizophrenia and schizoaffective disorder pa-tients treated with clozapine, olanzapine, risperidone, or haloperidol // J Clin Psychia-try. – 2004. – Vol.65(1). – P.57-61.
  19. Turrone P, Kapur S, Seeman MV, Flint AJ. Elevation of prolactin levels by atypical an-tipsychotics // Am J Psychiatry. – 2002. – Vol.159(1). – P.133-153.
  20. Nakajima M, Terao T, Iwata N, Nakamura J. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia // Pharmacopsychiatry. – 2005. – Vol.38(1). – P.17-19.
  21. Чомский А.Н. Влияние побочных эффектов атипичных антипсихотиков на те-рапевтический процесс у больных шизофренией: атореф.дис. ..канд.мед.наук. – Санкт-Петербург, 2008. – 26 с.
  22. BUNKER, MARK T.; MARKEN, PATRICIA A.; SCHNEIDERHAN, MARK E.; RUEHTER, VALERIE L. Attenuation of Antipsychotic-Induced Hyperprolactinemia with Clozapine // Journal of Child and Adolescent Psychopharmacology. – 1997. – Vol.7(1). – P.65–69.
  23. Lu ML, Shen WW, Chen CH. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole // Prog Neuropsychopharmacol Biol Psychiatry. – 2008. – Vol.32(8). – P.1978-1981.
  24. Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study // Schizophr Res. – 2009. – Vol.107(3). – P.218-222.
  25. Zhuo C, Xu Y, Wang H, et al. Safety and Efficacy of High-Dose Vitamin B6 as an Adjunctive Treatment for Antipsychotic-Induced Hyperprolactinemia in Male Patients With Treatment-Resistant Schizophrenia // Front Psychiatry. – 2021. – Vol.12. – P.68-74.
  26. Kirkpatrick B, Carpenter WT, Maeda K, Buchanan RW, Breier A, Tamminga CA. Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients. Biol Psychiatry. 1992 Dec 1;32(11):1049-54.
  27. Jen YW, Hwang TJ, Chan HY, Hsieh MH, Liu CC, Liu CM, Hwu HG, Kuo CH, Lin YT, Chien YL, Chen WJ. Abnormally low prolactin levels in schizophrenia patients af-ter switching to aripiprazole in a randomized trial: a biomarker for rebound in psychot-ic symptoms? // BMC Psychiatry. – 2020. – Vol.20(1). – P.552-558.
  28. Dorevitch A, Aronzon R, Stark M. Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia // Acta Obstet. Gyne-col. Scand. – 1991. – Vol.70. – P.375–376.
  29. Chang SC, Chen CH, Lu ML. Cabergoline-induced psychotic exacerbation in schizo-phrenic patients // Gen Hosp Psychiatry. – 2008. – Vol.30. – P.378–380.
  30. Pollice R, Di Giovambattista E, Tomassini A, Di Pucchio A, Mazza M, Di Michele V, Roncone R, Casacchia M. Iperprolattinemia sintomatica da risperidone in pazienti gio-vani affetti da schizofrenia e trattamento con cabergolina: studio di efficacia e tol-lerabilità [Risperidone-induced symptomatic hyperprolactinemia in youth with schizo-phrenia: efficacy and tolerability of cabergoline treatment] // Clin Ter. – 2007. – Vol.158(2). – P.121-126.
  31. Tollin SR. Use of the dopamine agonists bromocriptine and cabergoline in the man-agement of risperidone-induced hyperprolactinemia in patients with psychotic disor-ders // J Endocrinol Invest. – 2000. – Vol. 23(11). – P.765-70.
  32. Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, Joe SH. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study // Psychiatry Clin Neurosci. – 2010. – Vol.64(1). – P.19-27.
  33. Буланов В.С., Горобец Л.Н., Литвинов А.В. Синдром нейролептической гипер-пролактинемии у больных с параноидной шизофренией и его коррекция кабер-голином // Современная терапия психических расстройств. – 2016. – № 1. – С. 17–23.
  34. Sabuncu T, Arikan E, Tasan E, Hatemi H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients // Intern Med. – 2001. – Vol.40(9). – P.857-861.
  35. Горобец Л.Н., Буланов В.С. Сравнительная эффективность и переносимость коррекционной терапии каберголином (Достинексом) и бромокриптином син-дрома нейролептической гиперпролактинемии у больных с психическими расстройствами // Психиатрия и психофармакотерапия. — 2011. — Том 13. - №1. — С. 22-27.
  36. Crosignani PG. Current treatment issues in female hyperprolactinaemia // Eur. J. Ob-stet. Gynecol. Reprod. Biol. – 2006. – Vol.125. – P.152– 164.
  37. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally se-lective actions at dopamine D2 receptor-mediated signaling pathways // Neuropsychopharmacology. – 2007. – Vol. 32. – P.67–77.
  38. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology // Neuropsychopharmacology. – 2003. – Vol.28(8). – P.1400-1411.
  39. Rainka, M.M., Capote, H.A., Ross, C.A. and Gengo, F.M. Attenuation of risperidone-induced hyperprolactinemia with the addition of aripiprazole // Journal of Clinical Pharmacy and Therapeutics. – 2009. – Vol.34. – P.595-598.
  40. Zhi P, Wang Y, Quan W, Su Y, Zhang H. Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level // Neuropsychiatr Dis Treat. – 2018. – Vol.5. – P. 117-124.
  41. Chen LJ, Zhuo ZH, Zhuang H. A study of aripiprazole in sulpiride induced male hy-perprolactinemia // J Clin Psychiatry. – 2010. – Vol.20. – P. 304–305.
  42. Saitis M, Papazisis G, Katsigiannopoulos K, Kouvelas D. Aripiprazole resolves amisul-pride and ziprasidone-induced hyperprolactinemia // Psychiatry Clin Neurosci. – 2008. – Vol.62(5). – P. 624- 629.
  43. Raghuthaman G, Venkateswaran R, Krishnadas R. Adjunctive aripiprazole in risperi-done-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial // BJPsych Open. – 2015. – Vol.1(2). – P.172-177.
  44. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, Shon JH, Conley RR. Ad-junctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial // Am J Psychiatry. – 2007. – Vol.164(9). – P.1404-1410.
  45. Li X, Tang Y, Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials // PLoS One. – 2013. – Vol.8(8). – P.71-79.
  46. Chen CK, Huang YS, Ree SC, Hsiao CC. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics // Prog Neuropsychopharmacol Biol Psychiatry. – 2010. – Vol.34(8). – P.1495-1499.
  47. Paulzen M, Gründer G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole // Int J Neuropsychopharmacol. – 2007. – Vol.10(1). – P.149-151.
  48. Xu LP, Ji JY, Shi H, Zhai FL, Zhang B, et al...A control study of aripiprazole in the treatment of hyperprolactinemia by antipsychotics // Chin J of Behavioral Med.- 2006. – Vol.3. – P.718–720
  49. Arnone D. Review of the use of Topiramate for treatment of psychiatric disorders // Ann Gen Psychiatry. – 2005. – Vol. 4. – P.15-19.
  50. Correll C.U., Maayan L, Kane J, Hert M.D., Cohen D. Efficacy for psychopathology and body weight and safety of topiramate-antipsychotic cotreatment in patients with schizophrenia spectrum disorders: results from a meta-analysis of randomized con-trolled trials // J Clin Psychiatry. – 2016. – Vol.77. – P. 746-756.
  51. Wang C, Shi W, Xu J, Huang C, Zhu J. Outcomes and safety of concomitant topir-amate or metformin for antipsychotics-induced obesity: a randomized-controlled trial // Ann Gen Psychiatry. – 2020. – Vol.10. – P.19-23.
  52. Huang Y, Ma H, Wang Y, Peng M, Zhu G. Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia // Neuropsychiatr Dis Treat. – 2017. – Vol.24(13). – P.1395-1397.
  53. Apud J.A., Racagni G, Iuliano E, Cocchi D, Casanueva F, Muller E.E. Role of central nervous system-derived or circulating gamma-aminobutyric acid on prolactin secretion in the rat // Endocrinology. – 1981. – Vol.108. – P.1505-1510
  54. Debeljuk L, Goijman S, Seilicovich A, Diaz M.C., Rettori V.B. Current concepts: II. Effect of aminooxyacetic acid and bicuculline on prolactin release in castrated male rats // Life Sci. – 1980. – Vol. 27. – P. 2025-2029.
  55. Nagy G.M., Bodnar I, Banky Z, Halasz B. Control of prolactin secretion by excitatory amino acids // Endocrine. – 2005. – Vol.28. – P.303-308.
  56. Huang YL, Peng M, Zhu G. Topiramate in the treatment of antipsychotic-induced hy-perprolactinemia // Med Hypotheses. – 2020. – Vol.138. – P. 157-159.
  57. Kusakawa S, Tohei A, Jaroenporn S, Watanabe G, Taya K. Inhibition of stress-induced adrenocorticotropin and prolactin secretion mediating hypophysiotropic fac-tors by antagonist of AMPA type glutamate receptor // J Reprod. – 2007. – Vol.53. – P.545-554.
  58. Bodnar, Z. Banky, D. Zelena, B. Halasz. Glutamate receptor antagonist infused into the hypothalamic suprachiasmatic nuclei interferes with the diurnal fluctuations in plasma prolactin and corticosterone levels and injected into the mesencephalic dorsal raphe nucleus attenuates the suckling stimulus-induced release of prolactin of the rat // Brain Res Bull. – 2009.- Vol. 80. – P. 9-16
  59. Abbud R, Smith M.S. Altered luteinizing hormone and prolactin responses to excitato-ry amino acids during lactation // Neuroendocrinology. – 1993. – Vol. 58. – P. 454-464.
  60. Delitala G, Masala A, Alagna S. Suppression of pimozide-induced prolactin secretion by piridoxine (vitamin B6) // Biomedicine – 1977. – Vol. 27. – P.191–194.
  61. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, E. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study // J Clin Psychiatry. – 2007. – Vol.68(11). – P.1648-1654.
  62. Miodownik C, Lerner V, Statsenko N, Dwolatzky T, Nemets B, Berzak E, Bergman J. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study // Clin Neuropharmacol. – 2006. – Vol.29(2). – P.68-72.
  63. Scarpello J.H., Howlett H.C. Metformin therapy and clinical uses // Diab Vasc Dis Res. – 2008. – Vol.5. – P.157-167.
  64. Billa E, Kapolla N, Nicopoulou S.C., Koukkou E., Venaki E, Milingos S, Antsaklis A, Adamopoulos D.A. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syn-drome // Gynecol. Endocrinol. – 2009. – Vol.25. – P.427-434
  65. Krysiak R, Okrzesik J, Okopien B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study // Endocrine. – 2015. – Vol. 49. – P.242-249.
  66. Zheng, Wei; Yang, Xin-Hu; Cai, Dong-Bin; Ungvari, Gabor S; Ng, Chee H; Wang, Nan; Ning, Yu-Ping; Xiang, Yu-Tao. Adjunctive metformin for antipsychotic-related hyperprolactinemia: A meta-analysis of randomized controlled trials // Journal of Psy-chopharmacology. – 2017. – Vol.4. – P.192-206.
  67. Wang D, Wong HK, Zhang L, McAlonan GM, Wang XM, Sze SC, Feng YB, Zhang ZJ. Not only dopamine D2 receptors involved in Peony-Glycyrrhiza Decoction, an herbal preparation against antipsychotic-associated hyperprolactinemia // Prog Neuro-psychopharmacol Biol Psychiatry. – 2012. – Vol.3. – P.332-338.
  68. Zheng W, Cai DB, Li HY, et al. Adjunctive Peony-Glycyrrhiza decoction for antipsy-chotic-induced hyperprolactinaemia: a meta-analysis of randomised controlled trials // Gen Psychiatr. – 2018. – Vol.31(1). – P. 123-127.
  69. Wu J. N., Wang L. Y., Liu W. D., Du W. S., Liu W. B. Efficacy of 2. 5,10,15 mg ari-piprazole in treating amisulpride and risperidone-induced hyperprolactinemia // Chin J Biochem Pharm. – 2016. – Vol. 1. – P.114–115.
  70. Yang P, Li L, Yang D, et al. Effect of Peony-Glycyrrhiza Decoction on Amisulpride-Induced Hyperprolactinemia in Women with Schizophrenia: A Preliminary Study // Evid Based Complement Alternat Med. – 2017. – Vol.13. – P.47-52.
  71. Man SC, Li XB, Wang HH, Yuan HN, Wang HN, Zhang RG, Tan QR, Wong HK, McAlonan GM, Wang CY, Zhang ZJ. Peony-Glycyrrhiza Decoction for Antipsychot-ic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Con-trolled Trial // J Clin Psychopharmacol. – 2016. – Vol.36(6). – P.572-579.
  72. Yuan H. N., Wang C. Y., Feng X. J., Liu R. M., Zhang J. Z. Controlled study of shaoyao-gancao decoction and bromicripton in hyperprolactinemia // J Clin Psychol Med. – 2005. – Vol. 15(6). – P.337–338.
  73. Görler K, Öhlke D, Soicke H. Iridoid derivatives from Vitex agnus-castus // Planta Med. – 1985. – Vol.50. – P.530–531.
  74. Hirobe C, Qiao ZS, Takeya K, Itokawa H. Cytotoxic flavonoids from Vitex agnus-castus // Phytochemistry. – 1997. – Vol.46. – P.521–554.
  75. Senatore F, Napolitano F, Ozcan M. Chemical composition and antibacterial activity of essential oil from fruits of Vitex agnus-castus L. (Verbenaceae) growing in Turkey // J Essent Oil-Bear Plants. – 2003. Vol.6. – P.185–190.
  76. Ono M, Nagasawa Y, Ikeda T, Tsuchihashi R, Okawa M, Kinjo J, Yoshimitsu H, No-hara T. Three new diterpenoids from the fruit of Vitex agnus-castus // Chem Pharm Bull. – 2009. – Vol.57. – P.1132–1135.
  77. Ooi SL, Watts S, McClean R, Pak SC. Vitex Agnus-Castus for the Treatment of Cy-clic Mastalgia: A Systematic Review and Meta-Analysis // J Womens Health (Larchmt). – 2020. – Vol.29(2). – P.262-278.
  78. van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials // Planta Med. – 2013. – Vol.79(7). – P. 562-575.
  79. Csupor D, Lantos T, Hegyi P, Benkő R, Viola R, Gyöngyi Z, Csécsei P, Tóth B, Vasas A, Márta K, Rostás I, Szentesi A, Matuz M. Vitex agnus-castus in premenstrual syn-drome: A meta-analysis of double-blind randomised controlled trials // Complement Ther Med. – 2019. – Vol. 47. – P.102-110.
  80. Meier B, Berger D, Hoberg E, Sticher O, Schaffner W. Pharmacological activities of Vitex agnus-castus extracts in vitro // Phytomedicine. – 2000. – Vol.7(5). – P. 373–381.
  81. Męczekalski B, Czyżyk A. Vitex Agnus Castus w leczeniu hiperprolaktynemii i zaburzeń cyklu miesiączkowego - opis przypadku [Vitex Agnus Castus in the treat-ment of hyperprolactinemia and menstrual disorders - a case report] // Pol Merkur Le-karski. – 2015. – Vol. 39(229). – P.43-46.
  82. Погодин О. К., Власова Т. А., Гуменюк Е. Г. Рациональный подход к лечению функциональной гиперпролактинемии при бесплодии у женщин // Журнал акушерства и женских болезней. – 2010. – №3. – С. 12-17.
  83. Яворская С.Д. Место фитотерапии в лечении пациенток с гиперпролактинеми-ей // Гинекология. - 2013. - Т. 15. - №4. - C. 28-30.
  84. Сметник В.П., Бутарева Л.Б. Опыт применения фитопрепарата «Циклодинон» («Агнукастон») у пациенток с недостаточностью функции желтого тела и ги-перпролактинемией // Проблемы репродукции. – 2005. – №5. – C. 1-4
  85. Стрельцова Т.Р., Симонова Н.Р. Клинический опыт негормональной коррекции недостаточности лютеиновой фазы у женщин репродуктивного возраста // Здоровье женщины. – 2019. – № 4 (140). – С. 24-26.
  86. Milewicz A, Gejdel E, Sworen H, Sienkiewicz K, Jedrzejak J, Teucher T, Schmitz H. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hy-perprolactinemia. Results of a randomized placebo-controlled double-blind study // Arzneimittel-Forschung (Drug Res). – 1993. Vol.64(7). – P.752–756.
  87. Kilicdag E, Tarim E, Bagis T, Erkanli S, Aslan E, Ozsahin K, Kuscu E. Fructus agni casti and bromocriptine for treatment of hyperprolactinemia and mastalgia // Int J Gy-necol Obstet. – 2004. – Vol.85(3). – P.292–293.
  88. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlová-Wuttke D. Chaste tree (Vitex agnus-castus) // Pharmacology and clinical indications. – 2003. – Vol. 10(4). – P. 348–357.
  89. Bornhorst HL. Growing native Hawaiian plants: A how-to guide for the gardener // Honolulu: The Bess Press. – 1996. – P.26–27.

Скачивания

Данные скачивания пока недоступны.